Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Placebo-controlled, Multicenter Phase II Study of AK102 in the Treatment of Hypercholesterolemia Patients at Very High or High Risk of Cardiovascular Disease

Next Previous
Trial Profile

A Double-blind, Randomized, Placebo-controlled, Multicenter Phase II Study of AK102 in the Treatment of Hypercholesterolemia Patients at Very High or High Risk of Cardiovascular Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ebronucimab (Primary) ; Ezetimibe; HMG-CoA reductase inhibitors
  • Indications Dyslipidaemias; Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Akeso Biopharma

Most Recent Events

  • 16 Dec 2022 Status changed to completed, as per results presented at the American Heart Association Scientific Sessions 2022.
  • 07 Nov 2022 Primary endpoint (Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 12) has been met, as per results presented at the American Heart Association Scientific Sessions 2022.
  • 07 Nov 2022 Results assessing the safety, efficacy of ebronucimab and further identify the optimal dosing scheme in patients with hyperlipidemia, presented at the American Heart Association Scientific Sessions 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top